A third-quarter revenue beat with soft fourth-quarter guidance, excessive valuations, and scepticism about its forward growth are red flags. More downside for Fortinet after its earnings miss?
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?